Associate Professor & Director, Carleton Mass Spectrometry Centre (CMSC), Department of Chemistry, Carleton University Associate Professor, Institute of Biochemistry, Carleton University Full Biography Cancers of Interest Blood Bone Breast Colorectal Liver Ovarian Pancreatic Prostate Skin Soft Tissue Sarcoma Projects at BioCanRx Development of Supporting Analytical Assays and Regulatory Compliance Package for Viral… Read more »
Tag: Prostate cancer
Sachdev Sidhu
Professor, Donnelly Centre, University of Toronto Full Biography Cancers of Interest Bladder, Blood, Brain, Breast, Colorectal, Gastric, Head and Neck, Kidney, Liver, Lung, Neuroblastoma, Ovarian, Pancreatic, Prostate, Skin Research and clinical approaches The Sidhu lab studies the relationships between protein structure and function, using phage display in conjunction with high-throughput screening and… Read more »
Harman Sekhon
Chief, Division of Anatomic Pathology, Ottawa Hospital; Regional Head and Director of Anatomic Pathology, Eastern Ontario Regional Laboratory Association (EORLA); Regional Cancer Pathology Lead, Cancer Care Ontario (CCO) Full Biography Cancers of Interest Lung Ovarian Prostate Projects at BioCanRx Interrogation of Biomarkers in Patient Samples from a Phase Ib Trial of the… Read more »
Brad Nelson
Scientific Co-Director, BC Cancer Immunotherapy Program (Deeley Research Centre) Professor of Biochemistry/Microbiology, University of Victoria Professor of Medical Genetics, University of British Columbia Full Biography Projects at BioCanRx Enabling a Phase I/II Multicenter Clinical Trial of a Novel Single Domain (sd)CD-22-specific Camelid-derived Chimeric Antigen Receptor (CAR) T-cell Therapy Interrogation of Biomarkers in… Read more »
Brian Lichty
PhD, Associate Professor, Pathology and Molecular Medicine, McMaster Full Biography Cancers of Interest Breast Cervical Gynecological Lung Prostate Skin Projects at BioCanRx Development of a Virally Programmed Exosome-based Cancer Vaccine Platform COMBINING ONCOLYTIC VACCINE THERAPY WITH ADOPTIVE CELL THERAPY TO TARGET CANCERS EXPRESSING MAGE-A3 A Phase 1/1b, Multicenter, Open-label Trial… Read more »
Aly-Khan Lalani
Assistant Professor, Oncology, McMaster University Full Biography Cancers of Interest Bladder Gastrointestinal Stromal Tumours (GIST) Genitourinary Kidney Prostate Soft Tissue Sarcoma Testicular Projects at BioCanRx Phase II CYTOSHRINK Trial: Cytoreductive Stereotactic Hypofractionated Radiotherapy with Combination Ipilimumab and Nivolumab for Metastatic Kidney Cancer
Steven Jones
Canada Research Chair in Computational Genomics, University of British Columbia Professor, Medical Genetics/ Genetics Graduate Program, University of British Columbia Director Bioinformatics, Genome BC Bioinformatics Platform, Genome BC Founding Director, CIHR/MSFHR Bioinformatics Training Program Director, Bioinformatics Graduate Program, University of British Columbia Full Biography Cancers of Interest Bladder, Blood, Bone, Brain, Breast, Cervical,… Read more »
Naoto Hirano
Senior Scientist, Princess Margaret Cancer Centre Full Biography Cancers of Interest Blood, Breast, Lung, Ovarian, Pancreatic, Prostate, Skin, Soft Tissue Sarcoma Research Interests and Clinical Approach Dr. Hirano’s research team is particularly interested in understanding how the interactions between T cells and antigen-presenting cells affect priming, expansion, persistence and differentiation of T… Read more »
Jean-Simon Diallo
Senior Scientist, Cancer Therapeutics Program, Ottawa Hospital Research Institute Associate Scientist, Faculty of Medicine, University of Ottawa Full Biography Cancers of Interest Sarcoma Prostate Breast Research Interests and Clinical Approach Oncolytic Virotherapy Viral sensitizers Combination Immunotherapy Projects at BioCanRx Development of Supporting Analytical Assays and Regulatory Compliance Package for Viral Sensitizer… Read more »
Gregory Dekaban
Robarts Scientist and Professor, Western University Full Biography Cancers of Interest Blood Prostate Projects at BioCanRx In vivo human therapeutic cell tracking using a [19F]-perfluorocarbon cellular MRI contrast agent: Phase I feasibility and preliminary safety trial